Cencora, Inc. $COR Shares Purchased by T. Rowe Price Investment Management Inc.

T. Rowe Price Investment Management Inc. raised its position in Cencora, Inc. (NYSE:COR) by 160.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 6,700,091 shares of the company’s stock after buying an additional 4,123,795 shares during the quarter. Cencora makes up approximately 1.4% of T. Rowe Price Investment Management Inc.’s holdings, making the stock its 9th largest holding. T. Rowe Price Investment Management Inc.’s holdings in Cencora were worth $2,262,956,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of COR. Kemnay Advisory Services Inc. acquired a new stake in shares of Cencora during the 4th quarter valued at about $25,000. Oakworth Capital Inc. acquired a new position in Cencora in the fourth quarter worth approximately $26,000. Elyxium Wealth LLC acquired a new position in Cencora in the fourth quarter worth approximately $27,000. Archer Investment Corp raised its position in Cencora by 134.3% during the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after acquiring an additional 47 shares in the last quarter. Finally, Motiv8 Investments LLC bought a new stake in Cencora in the fourth quarter worth approximately $29,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Evercore set a $360.00 price target on shares of Cencora in a research note on Wednesday, April 8th. Barclays decreased their price objective on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a report on Wednesday, June 10th. Wells Fargo & Company lowered their target price on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research report on Monday, May 11th. Leerink Partners restated an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Finally, UBS Group upped their price target on Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Twelve equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and a consensus price target of $374.00.

Cencora Stock Performance

Shares of COR opened at $271.99 on Friday. The company has a market capitalization of $52.92 billion, a PE ratio of 20.86, a price-to-earnings-growth ratio of 1.50 and a beta of 0.59. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54. The company’s fifty day moving average price is $285.65 and its 200 day moving average price is $324.72.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The firm had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm’s revenue was up 3.9% on a year-over-year basis. During the same quarter last year, the company earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, analysts expect that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s payout ratio is currently 18.40%.

Cencora declared that its Board of Directors has approved a share repurchase plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to purchase up to 3.9% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.